These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38520045)

  • 1. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
    Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R
    J Psychopharmacol; 2024 May; 38(5):458-470. PubMed ID: 38520045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.
    Gukasyan N; Griffiths RR; Yaden DB; Antoine DG; Nayak SM
    J Psychopharmacol; 2023 Jul; 37(7):707-716. PubMed ID: 37291890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
    Szigeti B; Weiss B; Rosas FE; Erritzoe D; Nutt D; Carhart-Harris R
    Psychol Med; 2024 Jun; 54(8):1717-1724. PubMed ID: 38247730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS
    BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.
    Sakai K; Bradley ER; Zamaria JA; Agin-Liebes G; Kelley DP; Fish A; Martini V; Ferris MC; Morton E; Michalak EE; O'Donovan A; Woolley JD
    Psychopharmacology (Berl); 2024 Aug; 241(8):1617-1630. PubMed ID: 38687360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
    Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
    Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.
    Wu EQ; Greenberg PE; Yang E; Yu AP; Ben-Hamadi R; Erder MH
    J Med Econ; 2009 Jun; 12(2):124-35. PubMed ID: 19566483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
    Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C
    Cochrane Database Syst Rev; 2024 Sep; 9(9):CD015383. PubMed ID: 39260823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder.
    Stein DJ; Lopez AG
    Adv Ther; 2011 Nov; 28(11):1021-37. PubMed ID: 22057726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.